Nebbud (Budesonide)

Budesonide, the active ingredient in Nebbud, is a corticosteroid presented as an inhalation product for inhalation use. It reduces airway inflammation and hyper‑responsiveness in asthma and chronic obstructive pulmonary disease (COPD) in adults and children.

GNH USA supplies Nebbud as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebbud is an inhaled corticosteroid that targets inflammatory pathways in chronic respiratory diseases.

Asthma: improves symptom control and reduces the frequency of exacerbations. COPD: decreases dyspnoea, improves lung function and lowers the risk of flare‑ups. Chronic bronchitis: lessens airway inflammation and helps maintain airway patency.

Nebbud may cause a range of adverse reactions, most of which are related to local exposure of the airway.

Common Side Effects: - Oral candidiasis (thrush): fungal infection of the mouth. - Hoarseness or dysphonia: voice changes after inhalation. - Throat irritation or cough: irritation of the upper airway. - Headache: mild to moderate intensity. - Dry mouth: reduced salivation. - Nasal irritation: discomfort in the nasal passages.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: especially in patients with COPD. - Paradoxical bronchospasm: sudden worsening of breathing. - Severe allergic reaction: anaphylaxis or angioedema. - Ocular effects: cataracts or glaucoma with long‑term use. - Bone density loss: increased risk of osteoporosis with prolonged high‑dose therapy.

Before prescribing Nebbud, clinicians should consider several safety aspects.

Assess infection risk: avoid use in active untreated respiratory infections. Monitor oral health: advise regular mouth rinsing to prevent candidiasis. Avoid abrupt discontinuation: taper dose to prevent adrenal insufficiency. Use with spacer: a spacer device reduces oropharyngeal deposition. Screen for glaucoma or cataracts: long‑term use may affect intra‑ocular pressure. Store at room temperature: keep below 30 °C, in the original container, protected from moisture and direct sunlight.

Nebbud can interact with systemic drugs that affect corticosteroid metabolism or amplify pharmacologic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic budesonide exposure. - Live vaccines: immunosuppression could reduce vaccine efficacy. - Systemic glucocorticoids: additive risk of adrenal suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may lower budesonide levels. - Diuretics: may exacerbate hypokalaemia when combined with systemic steroids. - Other inhaled corticosteroids: increase total corticosteroid burden. - Antifungal azoles (e.g., fluconazole): may modestly raise budesonide concentrations.